Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UCHL1 | P09936 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | WNT3 | P56703 | 2/20 | 0.41 |
| ▸ | SFRP1 | Q8N474 | 2/20 | 0.41 |
| ▸ | HRH2 | P25021 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
| ▸ | SMO | Q99835 | 4/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.38 |
| ▸ | MET | P08581 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3511236 | 1.00 | UCHL1 (0.42) | UCHL1HSD17B10WNT3SFRP1HRH2 | |
| SCHEMBL13033653 | 0.89 | SMO (0.40) | SMOOPRM1OPRD1OGFRL1PDK2 | |
| SCHEMBL13033654 | 0.89 | SMO (0.40) | SMOOPRM1OPRD1OGFRL1PDK2 | |
| SCHEMBL3510738 | 0.87 | PDK2 (0.49) | SMOOPRM1OPRD1OGFRL1PDK2 | |
| SCHEMBL13033649 | 0.87 | PDK2 (0.43) | SMOOPRM1OPRD1OGFRL1PDK2 | |
| SCHEMBL13033825 | 0.87 | UCHL1 (0.47) | UCHL1HSD17B10HRH2HRH1SMO | |
| SCHEMBL13033820 | 0.87 | UCHL1 (0.47) | UCHL1HSD17B10HRH2HRH1SMO | |
| SCHEMBL13033822 | 0.85 | SMO (0.46) | UCHL1HSD17B10HRH2HRH1SMO | |
| SCHEMBL13033827 | 0.85 | SMO (0.46) | UCHL1HSD17B10HRH2HRH1SMO | |
| SCHEMBL13033726 | 0.84 | SMO (0.47) | UCHL1HSD17B10WNT3SFRP1HRH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8592463-B2 | Hedgehog pathway antagonists and therapeutic applications thereof | SIENA BIOTECH S.P.A. (IT) | 2013-11-26 | — | — | US | disclosed |
| US-20100286114-A1 | HEDGEHOG PATHWAY ANTAGONISTS AND THERAPEUTIC APPLICATIONS THEREOF | SIENA BIOTECH S.P.A. (IT) | 2010-11-11 | — | — | US | disclosed |
| EP-2227456-A2 | HEDGEHOG PATHWAY ANTAGONISTS AND THERAPEUTIC APPLICATIONS THEREOF | Siena Biotech S.p.A. (IT) | 2010-09-15 | — | — | EP | disclosed |
| WO-2009074300-A2 | HEDGEHOG PATHWAY ANTAGONISTS AND THERAPEUTIC APPLICATIONS THEREOF | SIENA BIOTECH S.P.A. (IT) | 2009-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286114-A1 | HEDGEHOG PATHWAY ANTAGONISTS AND THERAPEUTIC APPLICATIONS THEREOF | SHH, GLI1, SMO | UCHL1 4282/4885HSD17B10 3156/4885WNT3 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.